Ho-ho-ho! Gather ’round, my dear quality assurance elves, for I have a tale of technological wonder to share with you this fine season. It’s a story about the magical Mobius3D software, a clever little helper for all the good oncologists and physicists out there, ensuring their treatments are as precise as the toys we craft in our workshop.

In the land of patient-specific quality assurance (QA), there was a challenge that even the most skilled elves found tricky. You see, the traditional methods, much like trying to measure the right amount of sugar for Mrs. Claus’s cookies with a candy cane, were not always spot on. But then, like a bright star on a silent night, Mobius3D software came to town, promising to validate its dosimetric performance against the old faithful portal dose measurements using gamma analysis and confidence limits.

With a sleigh full of 240 QA plans for the Varian Halcyon linear accelerator, the Mobius3D was put to the test. It was commissioned with care, through beam data and plan verification, much like how we check our lists twice. Each plan then underwent QA through the electronic portal imaging device, coupled with the Portal Dosimetry software, and the Mobius3D, to see which could make the season bright.

The data were assessed using a gamma pass rate of over 95%, a standard as high as the North Pole’s snowdrifts. Portal measurements were evaluated using 3%/2 mm and 3%/3 mm criteria, whereas Mobius3D was analyzed at 3%/3 mm and 5%/3 mm, at the 10% threshold, much like we categorize toys by size and shape.

The results were as delightful as a warm mug of cocoa! Mobius at 5%/3 mm had mean gamma passes of 99.89% for volumetric-modulated arc therapy (VMAT) and 99.31% for intensity-modulated radiotherapy (IMRT), while the portal at 3%/2 mm had 99.99% and 99.96%, respectively. It was like comparing reindeer to reindeer, with only a red nose of difference!

For VMAT plans, Mobius3D at 5%/3 mm could perform like Portal at 3%/2 mm with just a 0.1% difference, especially for head/neck and pelvic/abdominal cases. It was like finding that the stockings were hung by the chimney with almost identical care! However, in IMRT-based treatments, a 0.7% difference meant that the performance and error identification in IMRT plans should be applied more carefully, like when we double-check the naughty or nice list.

The confidence limits were also quite jolly, with VMAT plans for Portal at 3%/2 mm and Mobius at 5%/3 mm being 99.93% and 99.42%, respectively, while for IMRT plans, they were 99.69% and 97.43%, respectively. It showed that at a 5%/3 mm criterion, the Mobius3D could yield percentage gamma pass rates similar to those obtained by Portal Dosimetry at 3%/3 mm and 3%/2 mm.

But remember, my elves, as with all magic, the software is largely dependent on the quality of the commissioned data. So, rigorous commissioning and a comprehensive QA program should be implemented, just as we ensure every toy is built to perfection before it’s loaded onto the sleigh.

And with that, my dear friends, may your treatments be merry and bright, and may all your QA checks be just right! 🎅🎄